Status:

COMPLETED

Serum Magnesium Concentration in Magnesium Sulfate Therapy for Severe Preeclampsia

Lead Sponsor:

Mỹ Đức Hospital

Conditions:

Severe Pre-Eclampsia

Eligibility:

FEMALE

18+ years

Brief Summary

Pregnant women diagnosed with pre-eclampsia with severe features will be treated with magnesium sulfate to prevent seizures. Magnesium sulfate will be administered according to My Duc Hospital's proto...

Detailed Description

This observational, longitudinal, prospective case-series aims to assess serum magnesium concentrations at specific times in pregnant women treated with magnesium sulfate for pre-eclampsia with severe...

Eligibility Criteria

Inclusion

  • Pregnant women
  • Aged ≥ 18
  • Diagnosed with pre-eclampsia with severe features, with or without chronic hypertension, as defined by the American College of Obstetricians and Gynecologists (ACOG) diagnosis criteria.
  • Provision of written informed consent to participate as shown by a signature on the patient consent form.

Exclusion

  • Impaired renal function (eGFR \< 60 mL/min/ 1,73 m2 or oliguria )
  • Occurrence of eclampsia before magnesium sulfate administration
  • Known hypersensitivity to the drug,
  • Severe myasthenia, atrioventricular block
  • A diminished level of consciousness.

Key Trial Info

Start Date :

March 15 2022

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

March 30 2024

Estimated Enrollment :

64 Patients enrolled

Trial Details

Trial ID

NCT05283473

Start Date

March 15 2022

End Date

March 30 2024

Last Update

January 7 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

My Duc Hospital

Ho Chi Minh City, Vietnam